Evidence map›Paper›PMID 28716733›Full record

ArticleBiochemical and biophysical research communications2017

ML327 induces apoptosis and sensitizes Ewing sarcoma cells to TNF-related apoptosis-inducing ligand.

Eric J Rellinger, Chandrasekhar Padmanabhan, Jingbo Qiao, Andrew Appert, Alex G Waterson, Craig W Lindsley, R Daniel Beauchamp, Dai H Chung

Abstract read
In one paragraph

Article in Biochemical and biophysical research communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Eric J RellingerSection of Surgical Sciences, Department of Surgery, United States; Department of Pediatric Surgery, Vanderbilt University Medical Center, Nashville, TN 37232, United States.
Chandrasekhar PadmanabhanSection of Surgical Sciences, Department of Surgery, United States.
Jingbo QiaoSection of Surgical Sciences, Department of Surgery, United States; Department of Pediatric Surgery, Vanderbilt University Medical Center, Nashville, TN 37232, United States.
Andrew AppertDepartment of Pediatric Surgery, Vanderbilt University Medical Center, Nashville, TN 37232, United States.
Alex G WatersonDepartment of Pharmacology, Vanderbilt Institute of Chemical Biology, United States.
Craig W LindsleyDepartment of Pharmacology, Vanderbilt Institute of Chemical Biology, United States.
R Daniel BeauchampSection of Surgical Sciences, Department of Surgery, United States; Department of Cancer Biology, United States; Department of Cell and Developmental Biology, United States.
Dai H ChungSection of Surgical Sciences, Department of Surgery, United States; Department of Cancer Biology, United States; Department of Pediatric Surgery, Vanderbilt University Medical Center, Nashville, TN 37232, United States. Electronic address: dai.chung@vanderbilt.edu.
Vanderbilt University Medical Center · USVanderbilt University · US

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
Surgical Oncology Training GrantT32CA106183 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI James Richard Goldenring · 2004 to 2026
$6.0M
Surgical Studies on the Role on Gastrin-releasing Peptide in NeuroblastomaR01DK061470 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CHUNG, DAI H. · 2003 to 2018
$4.7M
NCI NIH HHS P30 CA068485NCI NIH HHS T32 CA106183NIDDK NIH HHS P30 DK058404NIDDK NIH HHS R01 DK061470
6 · The paper itself

Abstract

Ewing sarcomas are rare mesenchymal-derived bone and soft tissue tumors in children. Afflicted children with distant metastases have poor survival despite aggressive therapeutics. Epithelial-to-mesenchymal transition in epithelial carcinomas is associated with loss of E-cadherin and resistance to apoptosis. ML327 is a novel small molecule that we have previously shown to reverse epithelial-to-mesenchymal transition features in both epithelial and neural crest-derived cancers. Herein, we sought to evaluate the effects of ML327 on mesenchymal-derived Ewing sarcoma cells, hypothesizing that ML327 initiates growth arrest and sensitizes to TNF-related apoptosis-inducing ligand. ML327 induced protein expression changes, increased E-cadherin and decreased vimentin, consistent with partial induction of mesenchymal-to-epithelial transition in multiple Ewing Sarcoma cell lines (SK-N-MC, TC71, and ES-5838). Induction of epithelial features was associated with apoptosis, as demonstrated by PARP and Caspase 3 cleavage by immunoblotting. Cell cycle analysis validated these findings by marked induction of the subG

Indexed as

Antigens, CDAntineoplastic AgentsApoptosisCadherinsCaspase 3Cell CycleCell Line, TumorDrug SynergismEpithelial-Mesenchymal TransitionGene Expression RegulationHumansIsoxazolesMesenchymal Stem CellsNiacinamidePoly(ADP-ribose) PolymerasesSarcoma, EwingAntigens, CDAntineoplastic AgentsCadherinsCASP3 protein, humanCaspase 3CDH1 protein, humanIsoxazolesML327 compoundNiacinamidePoly(ADP-ribose) PolymerasesSmall Molecule LibrariesTNF-Related Apoptosis-Inducing LigandTNFSF10 protein, humanVimentinApoptosisEpithelial-to-mesenchymal transitionEwing sarcomaIsoxazoleML327TRAIL

Identifiers

PMID28716733
PMCPMC5564678
OpenAlexW2736013706

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.